PGV-1 is a Potent Antimitotic Agent
Carcinogenesis may resulted from the malfunctioning of programmed cell death. Most of the anticancer drugs in<br />current use induce apoptosis in susceptible cells. The fact that disparate agent interacting with different targets seem<br />to induce cell death through some common mechan...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Universitas Gadjah Mada, Yogyakarta
2015-11-01
|
| Series: | Indonesian Journal of Biotechnology |
| Online Access: | http://journal.ugm.ac.id/ijbiotech/article/view/7796 |
| Summary: | Carcinogenesis may resulted from the malfunctioning of programmed cell death. Most of the anticancer drugs in<br />current use induce apoptosis in susceptible cells. The fact that disparate agent interacting with different targets seem<br />to induce cell death through some common mechanisms suggest that anticancer activity is determined by the ability<br />of inhibiting cell growth. Pentagamavunon-1 (PGV-1) is one of the curcumin analogues which showed to have<br />potency in inhibiting proliferation of T47D human breast carcinoma cells. The effects on T47D cells growth is<br />associated with cell cycle arrest in G2/M phase at the concentration of 2.5 ?M, followed by hyperploidy. The data on<br />polymerization assay, indicated that PGV-1 interact with tubulin in different manner from taxol. PGV-1 inhibit<br />tubulin polymerization on cell culture while taxol stabilized tubulin polymerization. Immunostainning data on<br />PGV-1 treated cells showed slightly tubulin condensation, while taxol treated cells showed tubulin condensation<br />distinctly at 12 minutes after releasing from depolymerizing agent.<br />In conclusion, PGV-1 represent a new microtubule inhibitor and has the potential to be developed for antimitotic<br />drug<br />Key words: Pentagamavunon-1, T47D, tubulin |
|---|---|
| ISSN: | 0853-8654 2089-2241 |